In the latest Synapse update, we've added a feature that displays bull's-eye charts for drug analysis and competitive landscape details (targets, indications, drug types).

Elicio Therapeutics, Inc. announced the first participant treated in a Phase 2 trial of ELI-002 7P, an adjuvant monotherapy for KRAS-mutant pancreatic ductal adenocarcinoma.

In biology, a terminator is a sequence of nucleotides that marks the end of a gene or operon during the transcription process.

Aclaris Therapeutics, working on immune-related treatments, shared initial Phase 2b results. They tested ATI-1777, a new topical JAK 1/3 inhibitor, on atopic dermatitis patients.

In clinical trials, a placebo is an inactive substance or other intervention that looks the same and tastes the same as the active drug being tested.

EyePoint Pharma reports initial participant receives treatment in early-stage VERONA study assessing EYP-1901 for diabetic eye swelling.

In clinical trials, a sham is a procedure or device that looks the same and feels the same as an active treatment being tested but doesn’t actually do anything.

Ariceum Therapeutics has submitted an application for a Clinical Trial Authorization (CTA) in the UK to conduct initial trials of its novel Iodine-123 tagged PARP inhibitor, targeting recurrent glioblastoma patients.

Clinical adverse events (AEs) are any unintended or harmful signs, symptoms, or conditions linked in time to the use of a medical product, regardless of causality.

Mirati Therapeutics, Inc. announced today that the European Commission has granted conditional approval for their medication, KRAZATI® (adagrasib).

GSK Plc agreed to buy Aiolos Bio, Inc. for $1 billion, plus up to $400 million in milestones, gaining access to Aiolos’s leading candidate, AIO-001, a long-acting anti-TSLP monoclonal antibody.

Xeris Biopharma has announced a global licensing agreement with Amgen for a subcutaneous teprotumumab injection using its XeriJect® system for Thyroid Eye Disease.